Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

232

Table 9.2 Instruments for patient reported outcome measurements in gout

Instrument Scale Mean score Effect size
VAS [ 7 ] 0–100 0.34
NRS [ 36 ] 0–10 1.62
HAQ [ 20 ] 0–3 0.59 0.62
GAQ [ 41 ] 0–100
SF-36 [ 42 ] 0–100 40.37 (PCS) 0.91 to 1.09 (across all
52.16 (MCS) SF-36 domains)
SF-36 PF-10 [ 43 ] 0–100 61.96
EQ-5D [ 21 ] 1–3 0.74
SF-6D [ 21 , 44 ] 0.29–1.00 0.67
Mobility scale [ 45 ] 0–80 75.5 (median)
VAS Visual Analog Scale, NRS Numeric Rating Scale, HAQ-DI Health Assessment Questionnaire-
Disability Index, GAQ v2.0 Gout Assessment questionnaire, version 2.0, SF-36 Short Form-36,
SF-36 PF-10 Short Form-36 Physical Functioning Subscale, EQ-5D EuroQol-5 dimensions, SF-
6D Short Form-6 Dimensions

Table 9.3 Visual analog scale scores for acute gout

Drugs/drug

comparisons Outcome

VAS score

change/absolute

in group 1

VAS score

change/absolute in

group 2

Mean change in

VAS scores

Oral prednisolone

plus IM Normal

Saline (Grp 1) vs.

oral indomethacin

plus IM diclofenac

(Grp 2) [ 48 ]

Pain at rest

at 2 h

−9.5 mm per

hour

−6.4 mm per hour MD: 3.2 mm

per hour a

95 % CI:

−0.78 to 7.14

N = 90 p = 0.12

Pain with

activity at

2 h

−19.2 mm per

hour

−20.3 mm per

hour

MD: 1.1 mm

per hour a

95 % CI:

−5.34 to 3.24

p = 0.63

Pain at rest

after

2 weeks

−0.7 mm per day −0.3 mm per day MD: 0.5 mm

per day a

95 % CI:

0.03 to 0.89

p = 0.04

Pain with

activity

after

2 weeks

−2.9 mm per day −1.7 mm per day MD: 1.2 mm

per day a

95 % CI:

0.44 to 2.00

p = 0.026

Oral prednisolone

and colchicine vs.

oral prednisolone

and colchicine with

topical ice [ 49 ]

Pain after

1 week

44.2 mm 77.5 mm p = 0.021 b

(continued)

J. Singh and N. Shah